Afya Limited

AFYA · NASDAQ

Market closed$13.90$-0.260000 (-1.84%)After hours $13.90 · 0.00%

Key statistics

Previous close$14.16
Open$14.01
Day high$14.19
Day low$13.76
52-week high$16.50
52-week low$13.00
Market cap1.25B
Volume48.29K
Average volume96.00K
P/E ratio7.94
Forward P/E
EPS1.75
Dividend yield+4.72%

Market context

Why it moved

AFYA shares declined modestly amid broad market pressure and a lack of company-specific catalysts, with thin trading volume suggesting limited investor conviction and general risk-off sentiment weighing on the Brazilian medical education stock.

What is happening

Recent company-specific developments and publisher coverage.

July 16, 2026Afya Limited closed modestly higher, outperforming a broader education sector weighed down by peer weakness, as investors highlighted the Brazilian medical education group's attractive dividend profile and valuation discount. A recent analysis flagged Afya's newly initiated dividend yield of 4.69%—placing it in the top 25% of U.S. dividend payers—alongside a low 41% payout ratio and consistent earnings growth, with Q1 2026 net income rising year-over-year to BRL 257 million. The positive sentiment around Afya contrasted with sharp declines in peer Strategic Education, which fell over 8% after missing quarterly earnings and revenue estimates.

1.2876

July 15, 2026Afya Limited edged slightly lower, closing down modestly as the Brazilian medical education group navigates a cautious analyst environment — eight brokerages maintain an average "Hold" rating with a consensus price target of $17.10, well above current levels, while JPMorgan trimmed its target to $21.00. Investor attention is also drawn to Afya's newly initiated dividend yielding ~4.7% and a low P/E of ~9.4x, with some analysts viewing shares as undervalued relative to fair value. Broader education sector pressure was notable, with peer Strategic Education (STRA) tumbling over 8% on the same day.

-0.4982

July 14, 2026Afya Limited closed modestly lower as analyst sentiment remains cautious, with an average "Hold" rating from eight brokerages and a consensus 12-month price target of $17.10 — well above current levels. JPMorgan recently trimmed its price target to $21.00 while maintaining a neutral stance, and Bank of America reaffirmed a neutral rating. Despite the soft analyst backdrop, Afya's newly initiated dividend (yielding ~4.7%) and a discounted valuation relative to estimated fair value are drawing income-focused investor interest, with Q1 2026 net income rising year-over-year to BRL 257 million.

-1.4035

July 13, 2026Afya Limited closed modestly lower, slipping about 0.9%, as analyst sentiment remains cautious with an average 'Hold' rating across eight brokerages and a consensus 12-month price target of $17.10 — well above current levels. JPMorgan recently trimmed its price target to $21.00 while maintaining a neutral stance, and notable insider selling activity has added some overhang. The broader education sector faces mixed signals, while the wider market is rotating toward defensive and value stocks ahead of key CPI data and bank earnings this week.

-0.904

July 10, 2026Afya Limited edged down modestly as options market activity draws attention to the Brazilian medical education company, with implied volatility surging on its September $30 call options — a striking level given the stock's current trading range near $14. Analysts hold a Zacks Rank #3 (Hold), though one analyst recently raised the current-quarter earnings estimate from $0.47 to $0.50 per share. Meanwhile, peer Lincoln Educational Services has been outperforming the broader education sector, and the consumer defensive sector faced headwinds on the day.

-0.6906

July 7, 2026Afya Limited closed modestly lower as a broad risk-on rotation out of defensive sectors weighed on the Brazilian education company's shares. With semiconductor and tech stocks surging Monday, investors pulled capital from consumer staples, healthcare, and utilities — the defensive corners where Afya often trades alongside — pressuring the stock. Adding to the cautious tone, a recent SEC Form 4 filing revealed Afya VP Junior Lelio de Souza sold his entire direct stake of 36,204 Class A shares at $15.00 on July 1, while Zacks flagged a surge in implied volatility in AFYA options, signaling heightened uncertainty among derivatives traders.

-0.6725

July 1, 2026Afya Limited edged higher, closing up about 1% amid notable insider selling activity, with two vice presidents offloading a combined ~51,500 Class A shares at prices between $14.80 and $15.00. Despite the insider sales, a valuation analysis pegs fair value at $17.25 per share — roughly 16% above current levels — citing Afya's digital initiatives, Medical Practice Solutions, and Continuing Education as drivers of recurring, higher-margin revenue and margin expansion.

1.0782

June 30, 2026Afya Limited closed essentially flat, edging down just 0.20% in a session where consumer defensive stocks broadly underperformed as technology led market gains. A SimplyWallSt analysis highlighted Afya as potentially undervalued, estimating a fair value of $17.25 per share versus the ~$14.87 close — a roughly 16% discount — citing the company's recovering share price but lagging longer-term returns. As a Brazil-focused medical education operator, Afya trades on dynamics distinct from U.S. peers, though broader sector headwinds and macro uncertainty around inflation and Fed policy weighed on sentiment.

-0.2017

Investing.com · June 11, 2026BofA raises Afya stock price target on tuition strength to $18Business Wire · June 10, 2026Afya Limited Releases 2025 Integrated ReportSimply Wall Street · May 10, 2026Afya’s Solid Earnings Meet Valuation Discount And AI HeadwindsBusiness Wire · May 8, 2026Afya Limited Announces First-Quarter 2026 Financial Results

Peers